These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26192476)

  • 21. Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth.
    Scioli MG; Artuso S; D'Angelo C; Porru M; D'Amico F; Bielli A; Gentile P; Cervelli V; Leonetti C; Orlandi A
    PLoS One; 2018; 13(9):e0203426. PubMed ID: 30192811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strigolactone Analogs: Two New Potential Bioactiphores for Glioblastoma.
    Antika G; Cinar ZÖ; Seçen E; Özbil M; Tokay E; Köçkar F; Prandi C; Tumer TB
    ACS Chem Neurosci; 2022 Mar; 13(5):572-580. PubMed ID: 35138812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting claudin-4 enhances chemosensitivity in breast cancer.
    Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
    Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
    Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination effects of SC144 and cytotoxic anticancer agents.
    Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N
    Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model.
    Al Faraj A; Shaik AS; Ratemi E; Halwani R
    J Control Release; 2016 Mar; 225():240-51. PubMed ID: 26827662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.
    Xie M; Vesuna F; Botlagunta M; Bol GM; Irving A; Bergman Y; Hosmane RS; Kato Y; Winnard PT; Raman V
    Oncotarget; 2015 Oct; 6(30):29901-13. PubMed ID: 26337079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B.
    Lin WL; Lee YJ; Wang SM; Huang PY; Tseng TH
    Eur J Pharmacol; 2012 Apr; 680(1-3):8-15. PubMed ID: 22329896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer.
    Yuan Q; Cai S; Zhang X; Liu Z; Li Z; Luo X; Xiong C; Wang J; Hu J; Ruan J
    Cancer Lett; 2012 Nov; 324(2):210-20. PubMed ID: 22652174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
    Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
    Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
    Kang HJ; Lee SH; Price JE; Kim LS
    Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel-based supramolecular hydrogel loaded with mifepristone for the inhibition of breast cancer metastasis.
    Zhao CC; Zhang CG; Sun X; Guo Q; Liu J; Liu Y; Hao YN; Feng G; Yang L; Liu H; Liu J
    Cancer Sci; 2022 Feb; 113(2):733-743. PubMed ID: 34859546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
    Boccia A; Virata C; Lindner D; English N; Pathan N; Brickelmaier M; Hu X; Gardner JL; Peng L; Wang X; Zhang X; Yang L; Perron K; Yco G; Kelly R; Gamez J; Scripps T; Bennett D; Joseph IB; Baker DP
    J Interferon Cytokine Res; 2017 Jan; 37(1):20-31. PubMed ID: 27835061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
    Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
    Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
    Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway.
    Peng Z; Wang Y; Fan J; Lin X; Liu C; Xu Y; Ji W; Yan C; Su C
    Sci Rep; 2017 Jan; 7():41254. PubMed ID: 28117370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo.
    Wang L; Wang C; Su B; Song Q; Zhang Y; Luo Y; Li Q; Tan W; Ma D; Wang L
    Biochem Cell Biol; 2013 Dec; 91(6):526-31. PubMed ID: 24219296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.